**Core Concept**
The question is testing the concept of postprandial hyperglycemia management, specifically the use of drugs that target the peak postprandial glucose levels. Postprandial hyperglycemia occurs due to the transient increase in glucose absorption from the gut after a meal, which is mainly regulated by the incretin hormones and insulin secretion.

**Why the Correct Answer is Right**
The correct answer is a drug that specifically targets postprandial hyperglycemia by enhancing the incretin effect, thereby facilitating a more physiological insulin release in response to meal intake. The drug works by inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades incretin hormones such as GLP-1 and GIP, thereby increasing their levels and enhancing insulin secretion in a glucose-dependent manner.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it refers to a medication primarily used for basal glucose control, not postprandial hyperglycemia.
**Option B:** This option is incorrect as it is an insulin analog that is used for both basal and bolus insulin therapy, not specifically for postprandial hyperglycemia.
**Option C:** This option is incorrect as it is a medication that primarily targets the renin-angiotensin-aldosterone system and is used for hypertension management, not postprandial hyperglycemia.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that postprandial hyperglycemia is a significant contributor to cardiovascular risk in patients with diabetes, and managing it effectively is crucial to preventing long-term complications.

**Correct Answer:** C. Sitagliptin